Carlo Finelli

发表

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Michele Cavo, Patrizia Tosi, Marco Gobbi, 2018, Blood.

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Michele Cavo, Patrizia Tosi, Marco Gobbi, 2016 .

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Benjamin L. Ebert, Michael R. Savona, John M. Bennett, 2019, Nature Medicine.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Valeria Santini, Robert Schoch, Pierre Fenaux, 2009, The Lancet. Oncology.